Xcout Intel
Auxilium Health
Auxilium Health is an Ontario-based company that develops biomaterials combining therapeutics and diagnostics. Its mission is to assist patients in healing more effectively through advanced medical technology.
Subscribe to see Auxilium Health’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Auxilium Health at a glance
Auxilium Health is a healthcare company headquartered in United States. It has raised at least $6.4M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Seed, raised $3.4M in July 2026. Xcout tracks 4 named people at Auxilium Health, including Isaiah Kaiser (Founder and CEO).
Auxilium Health leadership
- Isaiah KaiserFounder and CEO
- Isaiah KaiserExecutive Officer
- Duane ManciniDirector
- William MorgensternDirector
Auxilium Health funding rounds
At least $6.4M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $3.4M | — | |
| Seed | $3M | — | |
| Pre-Seed | Undisclosed | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Auxilium Health news
Investors
Auxilium Health competitors
A few of Auxilium Health's closest competitors — see the full list of competitors and alternatives →
S2Medical AB is a Swedish biomed-tech company that develops products and technologies for wound healing, infection control, and cosmeceuticals. The company utilizes biomaterials, regenerative medicine, and antimicrobial peptides to create solutions such as negative pressure therapy systems and treatments for multi-resistant bacterial infections, serving patients and healthcare providers.
Healome Therapeutics is an eye care therapeutics company headquartered in Birmingham, United Kingdom. The company focuses on developing more effective, safer, and practical treatments for vision-threatening ocular surface diseases.
Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Avadim Health, Inc. is a high-growth life sciences, healthcare, and wellness company based in Asheville, North Carolina. The firm develops and sells targeted topical products designed to improve immune health, neuromuscular health, and skin barrier function.
Spiderwort Biotechnologies Inc. is an Ottawa-based biotechnology innovator specializing in all-natural, plant-based biomaterials designed to support tissue regeneration and repair spinal cord injuries.
AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Get Auxilium Health's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Auxilium Health in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access